Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.64 +0.6%	$1.77	$1.21 ▼ $3.81	$40.50M	0.68	253,010 shs	83,292 shs
BCDA BioCardia	$2.85	$2.36	$1.63 ▼ $6.15	$14.52M	0.91	285,644 shs	51,670 shs
BLUE bluebird bio	$3.49 -5.9%	$4.22	$3.47 ▼ $28.60	$34.17M	0.27	365,846 shs	417,804 shs
ONCY Oncolytics Biotech	$0.52 -3.7%	$0.58	$0.47 ▼ $1.53	$44.87M	1	526,434 shs	113,240 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	+3.16%	+10.14%	-1.21%	-41.16%	-11.41%
BCDA BioCardia	+7.55%	0.00%	+41.79%	+20.25%	-51.78%
BLUE bluebird bio	+0.62%	-8.20%	-22.86%	-40.89%	-80.93%
ONCY Oncolytics Biotech	+4.86%	-2.00%	+10.00%	-30.63%	-54.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BCDA BioCardia	3.2163 of 5 stars	3.8	5.0	0.0	0.0	1.5	2.5	0.6
BLUE bluebird bio	2.4635 of 5 stars	3.1	4.0	0.0	0.0	1.2	1.7	1.3
ONCY Oncolytics Biotech	1.537 of 5 stars	3.5	3.0	0.0	0.0	1.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.67	1.63% Upside
BCDA BioCardia	3.50	Strong Buy	$25.00	777.19% Upside
BLUE bluebird bio	2.25	Hold	$44.60	1,177.94% Upside
ONCY Oncolytics Biotech	3.00	Buy	$4.33	734.62% Upside

Current Analyst Ratings Breakdown

Latest BCDA, ONCY, BLUE, and AADI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/31/2025	BLUE bluebird bio	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $8.00
3/10/2025	ONCY Oncolytics Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
3/10/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/10/2025	ONCY Oncolytics Biotech	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $5.00
2/24/2025	BLUE bluebird bio	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $5.00
2/24/2025	BLUE bluebird bio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral
2/21/2025	BLUE bluebird bio	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.62	N/A	N/A	$4.29 per share	0.38
BCDA BioCardia	$58K	250.31	N/A	N/A	($1.11) per share	-2.57
BLUE bluebird bio	$83.81M	0.41	N/A	N/A	$35.59 per share	0.10
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	N/A
BCDA BioCardia	-$11.57M	-$3.09	N/A	N/A	N/A	-1,999.77%	N/A	-208.38%	5/13/2025 (Estimated)
BLUE bluebird bio	-$211.91M	-$45.54	N/A	N/A	N/A	-565.74%	-322.46%	-53.17%	5/9/2025 (Estimated)
ONCY Oncolytics Biotech	-$20.56M	-$0.30	N/A	N/A	N/A	N/A	-141.15%	-84.73%	N/A

Latest BCDA, ONCY, BLUE, and AADI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	BLUE bluebird bio	-$2.42	N/A	N/A	N/A	$39.03 million	N/A
3/26/2025	Q4 2024	BCDA BioCardia	-$0.87	-$0.25	+$0.62	-$0.25	$0.02 million	$0.02 million
3/18/2025	Q4 2024	AADI Aadi Bioscience	-$0.30	-$0.67	-$0.37	-$0.67	$7.45 million	$7.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
BLUE bluebird bio	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
BCDA BioCardia	N/A	1.78	1.78
BLUE bluebird bio	0.37	0.51	0.33
ONCY Oncolytics Biotech	N/A	2.99	2.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
BCDA BioCardia	20.57%
BLUE bluebird bio	87.43%
ONCY Oncolytics Biotech	6.82%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
BCDA BioCardia	20.00%
BLUE bluebird bio	1.40%
ONCY Oncolytics Biotech	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
BCDA BioCardia	40	5.09 million	3.67 million	Optionable
BLUE bluebird bio	520	9.79 million	9.59 million	Optionable
ONCY Oncolytics Biotech	30	86.42 million	85.42 million	Not Optionable

BCDA, ONCY, BLUE, and AADI Headlines

Recent News About These Companies

Oncolytics Biotech to Discuss Q1 2025 Financial Results on May 14

May 8 at 6:10 PM | tipranks.com

Oncolytics Biotech (ONCY) to Release Earnings on Thursday

May 7 at 2:49 AM | americanbankingnews.com

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

May 6 at 7:00 AM | prnewswire.com

Oncolytics Biotech, Inc. Common Shares (ONCY) Latest After Hours Trades

May 4, 2025 | nasdaq.com

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

April 24, 2025 | prnewswire.com

As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments

April 14, 2025 | baystreet.ca

Oncolytics Biotech Secures $20 Million Funding for Pelareorep Development

April 10, 2025 | tipranks.com

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

April 10, 2025 | prnewswire.com

Oncolytics Biotech® and Pelareorep Discussed During

April 10, 2025 | kxan.com

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

April 10, 2025 | prnewswire.com

Oncolytics price target lowered to $3 from $5 at Maxim

March 10, 2025 | markets.businessinsider.com

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Earnings Call Transcript

March 8, 2025 | msn.com

Oncolytics Biotech Inc. (ONCY) Q4 2024 Earnings Call Transcript

March 7, 2025 | seekingalpha.com

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

March 7, 2025 | prnewswire.com

Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

March 5, 2025 | zacks.com

World Cancer Day Sparks Big Questions About Pollution, Genetics, and Innovation

February 27, 2025 | baystreet.ca

USA News Group: Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

February 27, 2025 | finanznachrichten.de

Oncolytics Biotech to Discuss 2024 Financial Results and Operational Highlights

February 25, 2025 | tipranks.com

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

February 25, 2025 | prnewswire.com

Oncolytics Biotech advances pancreatic, anal cancer trials

February 20, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock
By Jea Yu | April 21, 2025
View AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock
Hidden Gems: 3 Quiet Stocks With Loud Potential
By Nathan Reiff | April 23, 2025
View Hidden Gems: 3 Quiet Stocks With Loud Potential
Microsoft: A Blend of Growth and Value Amid Tariff Concerns
By Chris Markoch | April 15, 2025
View Microsoft: A Blend of Growth and Value Amid Tariff Concerns

BCDA, ONCY, BLUE, and AADI Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.64 +0.01 (+0.61%)

As of 05/8/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

BioCardia NASDAQ:BCDA

$2.85 0.00 (0.00%)

As of 04:00 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

bluebird bio NASDAQ:BLUE

$3.49 -0.22 (-5.93%)

As of 03:52 PM Eastern

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Oncolytics Biotech NASDAQ:ONCY

$0.52 -0.02 (-3.67%)

As of 04:00 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time